GENERALI, DANIELE
 Distribuzione geografica
Continente #
NA - Nord America 16.575
EU - Europa 8.765
AS - Asia 2.169
AF - Africa 35
SA - Sud America 32
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 4
Totale 27.599
Nazione #
US - Stati Uniti d'America 16.540
PL - Polonia 4.582
IT - Italia 1.155
SE - Svezia 1.122
CN - Cina 730
HK - Hong Kong 655
UA - Ucraina 441
DE - Germania 364
TR - Turchia 316
BG - Bulgaria 257
IE - Irlanda 255
FI - Finlandia 220
SG - Singapore 169
VN - Vietnam 115
GB - Regno Unito 84
BE - Belgio 45
IN - India 44
FR - Francia 43
ES - Italia 41
RU - Federazione Russa 37
MY - Malesia 35
BR - Brasile 25
CA - Canada 24
RO - Romania 23
NL - Olanda 22
IL - Israele 19
JP - Giappone 19
AU - Australia 17
CH - Svizzera 16
KR - Corea 13
SN - Senegal 12
AT - Austria 9
EE - Estonia 8
IR - Iran 8
TW - Taiwan 8
DK - Danimarca 7
EG - Egitto 7
MX - Messico 7
TH - Thailandia 7
CL - Cile 6
SA - Arabia Saudita 6
ZA - Sudafrica 6
CZ - Repubblica Ceca 5
GR - Grecia 5
JO - Giordania 5
MD - Moldavia 5
RS - Serbia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AM - Armenia 4
DZ - Algeria 4
HU - Ungheria 4
PK - Pakistan 4
PT - Portogallo 3
SC - Seychelles 3
CR - Costa Rica 2
DO - Repubblica Dominicana 2
HR - Croazia 2
NZ - Nuova Zelanda 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
GE - Georgia 1
ID - Indonesia 1
IQ - Iraq 1
LT - Lituania 1
LV - Lettonia 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
SI - Slovenia 1
Totale 27.599
Città #
Warsaw 4.571
Fairfield 2.614
Woodbridge 1.992
Houston 1.620
Ashburn 1.357
Ann Arbor 1.351
Chandler 1.115
Wilmington 1.101
Seattle 1.076
Cambridge 955
Hong Kong 646
Jacksonville 601
Princeton 472
Trieste 396
Izmir 308
Sofia 256
Dublin 255
Beijing 231
Boardman 153
San Diego 125
Dong Ket 108
Singapore 90
Dearborn 68
Falls Church 64
Helsinki 54
Bremen 51
Milan 46
Columbus 44
Redwood City 39
Norwalk 38
Brussels 37
Dongguan 36
Phoenix 35
Kerken 34
Chicago 30
Duino-Aurisina 30
Redmond 26
Rome 26
New York 22
Venice 22
Buffalo 21
Des Moines 21
Fremont 21
Hefei 21
Jinan 20
Nanjing 19
São Paulo 19
Udine 18
London 17
Padova 17
Pignone 17
Tel Aviv 17
Kunming 16
San Antonio 16
Amsterdam 15
Barcelona 15
Tappahannock 15
Guangzhou 14
Los Angeles 14
Shanghai 14
Dottingen 13
Madrid 13
Toronto 13
Boydton 12
Dakar 12
Florence 12
Hangzhou 12
Horia 12
Montegaldella 11
Seoul 11
Shenyang 11
Tokyo 11
Turin 11
Edinburgh 10
Lappeenranta 10
Nanchang 10
San Francisco 10
Zhengzhou 10
Fuzhou 9
Schoenwalde 9
Toenisvorst 9
Indiana 8
Paris 8
Pune 8
Vienna 8
Bangkok 7
Dallas 7
Tianjin 7
Venezia 7
Brescia 6
Council Bluffs 6
Freiburg im Breisgau 6
Grafing 6
Renton 6
Rho 6
Treviso 6
Turku 6
Baltimore 5
Bari 5
Bern 5
Totale 22.796
Nome #
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration 371
Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma 368
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer 334
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial 324
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study 319
Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? 312
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma 310
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene 309
Designing a broad-spectrum integrative approach for cancer prevention and treatment 305
Current challenges in HER2-positive breast cancer 304
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition 300
Advances in systemic therapy for metastatic breast cancer: future perspectives 298
Characterization of MTAP gene expression in breast cancer patients and cell lines 288
Isolated testicular metastasis from prostate cancer 288
Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer 279
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 278
Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer? 272
Broad targeting of angiogenesis for cancer prevention and therapy 270
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 269
NEODUCTGENESIS AS A PROGNOSTIC MARKER IN “DUCTAL” CARCINOMA IN SITU OF THE BREAST 266
Bevacizumab in small cell lung cancer 260
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer 254
Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes 251
Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer 246
Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts 242
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials 238
Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma 238
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit 234
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma 230
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 229
Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. 226
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 223
Inhibitors of Tumor Angiogenesis 212
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 201
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma 198
Abemaciclib: A CDK4/6 inhibitor for the treatment of HR+/HEeR2- advanced breast cancer 189
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 182
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study 170
Advances in systemic therapy for malignant mesothelioma: Future perspectives 169
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis 164
Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR 159
PROGNOSTIC ROLE OF TUMOR INFILTRATING LYMPHOCITES (TILS) IN EPITHELIOID PLEURAL MESOTHELIOMA 158
Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer 156
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment 154
CDK4/6 inhibitors in HER2-positive breast cancer 154
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data 151
The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis 149
Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis 147
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 141
Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? 140
Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers 140
null 137
RNA disruption and drug response in breast cancer primary systemic therapy 137
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 135
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer 134
Apatinib for the treatment of gastric cancer 134
Neoadjuvant treatment approach: The rosetta stone for breast cancer? 133
Ibrutinib: from bench side to clinical implications 132
Gene expression profiling in breast cancer: A clinical perspective 130
Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: A Meta-analysis 130
null 129
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer 128
The relevance of chemobrain in breast cancer survivors: An Italian exploratory study to measure incidence and psycho-social impact 128
Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer 127
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy 127
Practice patterns regarding drains management in breast surgery: Results of a survey of Senonetwork Italia breast centers 127
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 124
Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis 124
New omics information for clinical trial utility in the primary setting 123
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer 122
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials 121
Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: A rhythmometric analysis 120
Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status 120
Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis 120
Lenvatinib for the treatment of renal cell carcinoma 120
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 119
Biological therapies for metastatic breast cancer: Antiangiogenesis 119
Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients 117
Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer? 117
Colorectal cancer-screening program improves both short- and long-term outcomes: a single-center experience in Trieste 117
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010) 116
Positron emission tomography and neoadjuvant therapy of breast cancer 116
High-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk primary breast cancer 116
Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?[5] 115
Curcumin as an adjunct therapy and microRNA modulator in breast cancer 115
Targeting fibroblast growth factor receptor in breast cancer: A promise or a pitfall? 114
Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience 113
null 112
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 111
European inter-institutional impact study of MammaPrint 111
Is there a place for bevacizumab in patients with extensive-stage small cell lung cancer? 111
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer 111
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer 110
"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future? 110
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? 110
Inhibitors of tumor angiogenesis 109
Familial aggregation of gastric cancer with microsatellite instability** 109
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use 108
Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: Management considerations 108
Management of the side-effects of intravenous bisphosphonates: Targeting the serum parathyroid hormone elevation [6] 108
Totale 17.953
Categoria #
all - tutte 72.846
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.846


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019707 0 0 0 0 0 0 0 0 0 0 0 707
2019/20207.218 438 442 405 1.134 558 855 660 534 665 490 618 419
2020/20214.712 468 444 378 532 564 389 440 352 255 349 184 357
2021/20222.804 163 409 197 173 39 197 134 107 380 380 172 453
2022/20233.528 335 361 295 433 368 653 54 313 427 39 178 72
2023/20242.705 120 364 163 188 162 226 476 594 24 122 217 49
Totale 28.559